Suppr超能文献

一名支气管扩张症患者服用达比加群后出现大量咯血。

Massive haemoptysis following dabigatran administration in a patient with bronchiectasis.

作者信息

Hayama Manabu, Inoue Hideki, Wada Hiromichi, Mio Tadashi

机构信息

Respiratory medicine, National Hospital Organization Kyoto Medical Center, Kyoto-shi, Kyoto, Japan.

出版信息

BMJ Case Rep. 2014 Feb 19;2014:bcr2013201001. doi: 10.1136/bcr-2013-201001.

Abstract

We report a case of life-threatening haemoptysis after administration of dabigatran in a patient with bronchiectasis. A 72-year-old woman had received dabigatran at a dose of 110 mg twice daily for chronic atrial fibrillation. She was admitted to our hospital for cerebral infarction after a few days of self-interruption of dabigatran. After the diagnosis of cerebral infarction, administration of dabigatran was restarted. Seven days later, she suffered acute-onset massive haemoptysis and required mechanical ventilation. Dabigatran treatment was discontinued, and bronchial artery embolisation (BAE) was performed twice. The bleeding continued for 11 days, but she recovered and was discharged on day 58 after admission.

摘要

我们报告了1例支气管扩张症患者服用达比加群后出现危及生命的咯血病例。一名72岁女性因慢性心房颤动接受达比加群治疗,剂量为每日2次,每次110 mg。在自行中断达比加群几天后,她因脑梗死入住我院。脑梗死诊断明确后,重新开始服用达比加群。7天后,她突发大量咯血,需要机械通气。停用达比加群治疗,并进行了2次支气管动脉栓塞术(BAE)。出血持续了11天,但她康复了,并于入院后第58天出院。

相似文献

1
Massive haemoptysis following dabigatran administration in a patient with bronchiectasis.
BMJ Case Rep. 2014 Feb 19;2014:bcr2013201001. doi: 10.1136/bcr-2013-201001.
2
[Exfoliative esophagitis while taking dabigatran].
Dtsch Med Wochenschr. 2015 Apr;140(7):515-8. doi: 10.1055/s-0041-101313. Epub 2015 Mar 31.
3
[Dabigatran in prevention of stroke in atrial fibrillation: three years of clinical application].
Kardiologiia. 2014;54(2):79-85. doi: 10.18565/cardio.2014.2.79-85.
4
Dabigatran-induced acute hepatitis.
Clin Appl Thromb Hemost. 2012 Sep;18(5):549-50. doi: 10.1177/1076029611435840.
5
Ischemic stroke and intestinal bleeding under dabigatran in metabolic myopathy.
Cardiovasc Ther. 2013 Dec;31(6):e111-4. doi: 10.1111/1755-5922.12044.
6
The importance of postapproval data for dabigatran.
JAMA Intern Med. 2015 Jan;175(1):25. doi: 10.1001/jamainternmed.2014.6265.
8
9
Gastrointestinal bleeding under dabigatran.
J Postgrad Med. 2014 Apr-Jun;60(2):192-3. doi: 10.4103/0022-3859.132343.
10
Risk of major bleeding and the standard doses of dabigatran.
Eur J Intern Med. 2014 Jul;25(6):e73-5. doi: 10.1016/j.ejim.2014.02.005. Epub 2014 Mar 11.

引用本文的文献

1
Respiratory Pathology and Cardiovascular Diseases: A Scoping Review.
Open Respir Arch. 2024 Nov 23;7(1):100392. doi: 10.1016/j.opresp.2024.100392. eCollection 2025 Jan-Mar.
2
Population pharmacokinetic study of the effect of polymorphisms in the ABCB1 and CES1 genes on the pharmacokinetics of dabigatran.
Front Pharmacol. 2024 Nov 15;15:1454612. doi: 10.3389/fphar.2024.1454612. eCollection 2024.
4
Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study.
Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619886022. doi: 10.1177/1076029619886022.

本文引用的文献

1
Hemodialysis for the treatment of pulmonary hemorrhage from dabigatran overdose.
Am J Kidney Dis. 2013 Sep;62(3):591-4. doi: 10.1053/j.ajkd.2013.02.361. Epub 2013 Apr 16.
2
Dabigatran and postmarketing reports of bleeding.
N Engl J Med. 2013 Apr 4;368(14):1272-4. doi: 10.1056/NEJMp1302834. Epub 2013 Mar 13.
5
Urgent statement on antithrombotic therapy of atrial fibrillation.
Circ J. 2011;75(12):2719-21. doi: 10.1253/circj.cj-88-0026. Epub 2011 Nov 8.
9
Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): digest version.
Circ J. 2010 Nov;74(11):2479-500. doi: 10.1253/circj.cj-88-0001. Epub 2010 Oct 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验